Member Info for crumbs

I'm not sure I see any conflict there? CEPI are all about getting successful vaccines out to as many people as possible they are more a charity than a company... in fact at some point if scancells vax is a success they really will get involved...surely redmile would be over the moon for CEPI to be involved and or a pharma too...

Maybe what I'm getting at with CEPI is possibly they already have an idea of who it is they are going to be backing.

Well ok 2 months :)

Interestingly to me is that for the variant resitant CV19 call ... it is only open for a month and they are not doing the peer review process that they are doing for the betacoronavirus one which also has a 7 month opening...

'More information and application details

The BPCoV2 application will require one step, the submission of an Expression of Interest (EOI). The BPCoV2 call is open from April 1st to May 31st, 2021.'

Anyways what that indicates to me is if scancell are in with a chance there that news could come soon....

Another funny thing we appear here in this article about a UK startup... https://sifted.eu/articles/variant-proof-coronavirus-vaccine/
now this company claim:
'The team had already started speaking to investors about potential funding before Covid-19 hit, but found fundraising slow going. Until the pandemic hit, that is. Then, with the global spotlight on vaccine technology, so many potential investors expressed an interest that the Baseimmune team was hard-pressed to choose between them.'

Well if so we can be sure of the interest scancell has been getting I reckon....

BTW it indicates to me that scancell will have been looking at this novel Notts (Dr Dixon) developed delivery that is now being utilised for Covidity for a while maybe already with plans on developing it for future SCIBs.... covid has pushed this all ahead and thanks innovate UK for funding what may well prove very transformational for ImmunoBody no matter what happens with Covidity.... though you would think if it all works out there we are going to be in a really interesting place :)

Scancell are working very hard to derisk their platforms by making sure they give the best immune responses possible... I recommend reading the whole article... and it hints at possible future developments as scancells science never sleeps .

'The success of any cancer vaccine does not rely only on the ability of the vaccine to induce a robust immune response but also on the modification of the immune suppressive TME to enable the successful trafficking of T cells and the ability of these T cells to recognize and kill tumor cells. The tumor size, TMB and previous treatments will all influence the success of a cancer vaccine and this will vary among patients and cancer types. With huge improvements in the cancer vaccine field and a better knowledge of the TME with time cancer vaccines will start to show good clinical efficacy.'

oops linky :)
https://www.frontiersin.org/articles/10.3389/fimmu.2021.627932/full

'A delivery system based on modified cell penetrating peptide (CPP) based gene vectors, the Glycosaminoglycan (GAG)-binding enhanced transduction (GET) delivery system has been used to enhance delivery of nucleic acids for lung gene therapy and bone regeneration in vivo (143, 144). The GET peptides (143–150) are multi-domain sequences comprising of a heparan sulphate (HS) cell targeting sequence fused to a CPP for improved membrane association and synergistically enhanced intracellular delivery of therapeutic cargoes (145). GET peptides can deliver self-reporting cargo (monomeric red fluorescent protein; mRFP) into difficult to transduce cell types including mesenchymal stem cells (MSCs), human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). Delivery involves a heparin sulphate (HS) cell targeting system fused to a CPP and an endosomal escape peptide and a system which stabilizes particles to prevent aggregation and promote diffusion and cell uptake by PEGylation. The tripeptide complexes the DNA into nanoparticles and can be delivered by simple intramuscular injection. This tripeptide formulation has achieved exceptional results in DNA delivery applications in particular in lung, brain, and has huge potential in vaccine delivery.'

This will be what is being utilised for Covidity.

scancell on biotechradars err radar
https://biotechradar.eu/european-listed-biotech-landscape-2020-review-and-outlook-for-2021/2/

'The broadly protective vaccine against SARS-CoV-2 variants (BPCoV2) should have a minimal Target Product Profile (TPP) that aims to prevent disease caused by circulating SARS-COV-2 variants of concern and emergent variants of interest. Ideally, this minimal TPP should also prevent infection and transmission. The broadly protective Betacoronavirus (BPBC) vaccine will involve the research and development of novel immunogens and platform technologies and should have a minimal TPP that aims to protect against disease caused by the known Betacoronaviruses that already pose a significant epidemic or pandemic risk. An optimal TPP may additionally protect against novel Betacoronaviruses that pose a significant risk of spill over zoonoses and subsequent human transmission that results in new outbreaks.



More information and application details

The BPCoV2 application will require one step, the submission of an Expression of Interest (EOI). The BPCoV2 call is open from April 1st to May 31st, 2021.'

So looks like Covidity at least fits the first proposal:
'
– A broadly protective vaccine against new emerging variants and variants of concern of the SARS-CoV-2 virus, with funding up to 18-24 months to achieve clinical proof of concept.'

This opportunity will be open, worldwide, to research and development organisations with expertise in vaccine development.
>Up to US$200 million in funding to be allocated for development of vaccines that provide broad protection against SARS-CoV-2 and betacoronaviruses.
>R&D will focus on novel immunogens for use in vaccines that can elicit durable broadly protective immune responses.
>Funding call forms part of CEPI’s longer term $3.5bn investment strategy, announced earlier in March, 2021, which is being activated now to mitigate the urgent threat posed by COVID-19.
The call for proposals invites funding application for development of the following:

– A broadly protective vaccine against new emerging variants and variants of concern of the SARS-CoV-2 virus, with funding up to 18-24 months to achieve clinical proof of concept.

– A broadly protective Betacoronavirus vaccine with funding potentially awarded for up to 4 years to demonstrate clinical proof of concept.
https://cepi.net/news_cepi/cepi-launches-funding-call-to-advance-development-of-broadly-protective-coronavirus-vaccines/

It's the miracle of Easter! Now do something about this red tide :)

I think this is a different universal meaning

You can bet further ahead than it seems.... again I would not be surprised if CEPI funding came pre ph1 just because there is plenty to fund but certainly on ph1 positive results

I know it all gets funny around ISA time... nana always goes on a posting holiday for one:)
News will drop when it does but it does really feel close ...
And to be fair it is to be expected going off the given timelines .....

Que sara sara

moditope will be an injection combined with the adjuvant Amplivant...
electroporation was the best option at the time it was chosen for SCIB1 and indeed it works!... we all know the issues with it and this new 'simple non-toxic peptide delivery' Lindys words ...could be a game changer this trial is going to be very big for Dr Dixon as well... he finally gets his years of work into a clinical setting he is for sure going to want it to get the best shot and you can't think it will go forwards until every part of the team are happy.

Yeah great they are all working on the samples to different ends that could all come together

We know Lindy is also something of a talent spotter... If scancell were ever to come into the big time I have few doubts Lindy would bring in some brilliant scientists and their science...... better to keep Pfizer at arms length though lol

Of all the blurbs on the scientists working on the continuum program, only Lindy's contains a highlighted part(the part I put into capitals)... and it is her work that is actually working towards usable therapies....

Anyways no doubts we will hear something more from that and it is a great program UK again!... We ought to become the biotech powerhouse of the world

Again there certainly seems to be coming from continuum what and how much a part Lindy is a part of it yet to be known...

'Our online symposium revealed groundbreaking results that are set to be truly practice changing'
It makes perfect sense that the bloods and samples continuum has collected and that the scientists then work on contain answers to beating cancer....